Pharmacokinetic studies in hemodialysis patients.
Intermittent hemodialysis is the primary supportive therapy for patients with end-stage renal disease, who commonly receive several drugs to treat both their underlying disease and the conditions that arise during long-term hemodialysis therapy. Many of these drugs are dialyzable, and their hemodialytic removal may compromise therapeutic efficacy if appropriate supplementary doses are not given. Emergency hemodialysis may also be life-saving for patients who have received drug overdoses or have ingested toxic substances. Optimal therapy in both these clinical settings is critically dependent on the availability of reliable information from well-designed pharmacokinetic studies.
Atkinson
A J
AJ
Department of Molecular Pharmacology & Biochemistry, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Art_Atkinson@msn.com
Umans
J G
JG
D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D062787:Drug Overdose; D064420:Drug-Related Side Effects and Adverse Reactions; D004632:Emergency Medical Services; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism*; D011041:Poisoning / Q000628:therapy; D006435:Renal Dialysis
D004364:Pharmaceutical Preparations